Clinical Trials on Pneumonia in Japan

Total 91 results

Pfizer

Completed

Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)

Streptococcus Pneumoniae | Pneumococcal Vaccine

Japan
Kameda Medical Center
Merck Sharp & Dohme LLC; PPD; Osaka University

Completed

The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine

Influenza | Pneumococcal Pneumonia

Japan
Hamamatsu University

Completed

The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia

Chronic Disease | Eosinophilic Pneumonia

Japan
AstraZeneca

Completed

An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan (Evusheld DBR)

COVID-19

Japan
Pfizer

Completed

Special Investigation of COMIRNATY in the Population With Underlying Diseases

COVID-19

Japan
AnGes, Inc.

Completed

Study of COVID-19 DNA Vaccine (AG0302-COVID19)

COVID-19

Japan
AnGes, Inc.
Japan Agency for Medical Research and Development

Completed

Study of COVID-19 DNA Vaccine (AG0301-COVID19)

COVID-19

Japan
Pfizer

Completed

Drug Use Investigation of COMIRNATY Intramuscular Injection

COVID-19

Japan
Genova Inc.
Tokyo Shinagawa Hospital

Recruiting

Novaferon in Non-hospitalized Adult Patients With Mild COVID-19

Covid19

Japan
Meiji Seika Pharma Co., Ltd.

Recruiting

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales (Integral-2)

Acute Pyelonephritis | Complicated Intra-abdominal Infection | Complicated Urinary Tract Infection | Ventilator-associated Bacterial Pneumonia | Hospital-acquired Bacterial Pneumonia

Japan
Pfizer

Active, not recruiting

Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years

COVID-19 | SARS-CoV-2

Japan
ModernaTX, Inc.

Completed

Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination

Coronavirus Disease (COVID-19)

Japan
ModernaTX, Inc.

Completed

Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine

SARS-CoV-2

Japan
ModernaTX, Inc.

Completed

Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19

SARS-CoV-2

Japan
Takeda

Withdrawn

Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms

Coronavirus Disease (COVID-19)

Japan
Pfizer

Completed

A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

SARS-CoV-2 Infection

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects

Covid19

Japan
Kitasato University

Active, not recruiting

Study in COvid-19 Patients With iveRmectin (CORVETTE-01)

Covid19

Japan
Tohoku University

Completed

Vitamin D Supplementation Prevents Elderly Pneumonia

Bacterial Pneumonia

Japan
ModernaTX, Inc.

Completed

Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19

SARS-CoV-2

Japan
Bristol-Myers Squibb

Completed

A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in Japan

COVID-19

Japan
Okayama Research Investigator Organizing Network

Unknown

Intubation and Extubation Over 48 Hours Mechanical Ventilation (INDEX48)

Critical Illness | Pneumonia, Ventilator-Associated

Japan
Sanofi

Completed

Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia

Pneumonia

Japan
Humanity & Health Medical Group Limited
Tokyo University; Nihon University School of Medicine

Recruiting

Liver Injury After COVID-19 Vaccination

Subjects After COVID-19 Vaccination

Japan, Hong Kong
Takeda

Completed

A Study of TAK-919 in Healthy Japanese Adults (COVID-19)

Coronavirus Disease (COVID-19)

Japan
Takeda

Completed

A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Coronavirus Disease (COVID-19)

Japan
BioNTech SE
Pfizer

Completed

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

COVID-19 | SARS-CoV-2 Infection

Japan
Rohto Pharmaceutical Co., Ltd.

Completed

An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)

Severe Acute Respiratory Syndrome Coronavirus 2

Japan
Yubari Kibounomori
Health Research Foundation

Completed

Effects of the Oral Care With Vaccines for Pneumonia in Elderly; Going Home Together Both Physician and Dentist

Pneumonia

Japan
Rohto Pharmaceutical Co., Ltd.

Completed

A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)

SARS-CoV-2 Infection( COVID-19 )

Japan
Astellas Pharma Inc

Completed

A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia

Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis

Japan
Osaka General Medical Center
Wakayama Medical University; Nagasaki University; University of the Ryukyus; Kansai... and other collaborators

Completed

GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial

Ventilator Associated Pneumonia

Japan
AstraZeneca

Terminated

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19

Prevention of Infectious Disease Caused by SARS-CoV-2

Japan
Ono Pharmaceutical Co. Ltd

Completed

Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia

Community-acquired Pneumonia

Japan
North East Japan Study Group
Boehringer Ingelheim

Active, not recruiting

Japanese Idiopathic Interstitial Pneumonias Registry (JIPS)

Idiopathic Interstitial Pneumonia

Japan
Medicago
Mitsubishi Tanabe Pharma Corporation

Terminated

Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

SARS-CoV-2 Infection

Japan
Takeda

Completed

A Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Japan
AstraZeneca
Iqvia Pty Ltd

Completed

Study of AZD1222 for the Prevention of COVID-19 in Japan

COVID-19

Japan
AnGes, Inc.
Japan Agency for Medical Research and Development

Completed

Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)

COVID-19

Japan
AnGes, Inc.
Japan Agency for Medical Research and Development

Completed

Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)

COVID-19 Lower Respiratory Infection

Japan
Genova Inc.

Recruiting

Novaferon for COVID-19 Treatment Trial (NCTT-005)

Covid19

Japan
AstraZeneca

Completed

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA

Prevention of Infectious Disease Caused by SARS-CoV-2

Japan
Bayer

Completed

A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia

Pneumonia

Japan
Bayer

Terminated

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (RISE-IIP)

Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary

Belgium, Israel, Spain, United States, Switzerland, New Zealand, Greece, Portugal, Japan, Argentina, Canada, Denmark, France, Germany, Russian Federation, Turkey, Colombia, Saudi Arabia, Australia, Italy, United Kingdom
Pfizer

Completed

Disease Burden of Pneumonia, Meningitis and Bacteremia Among Children in Japan: Pneumonet Japan

Pneumococcal Disease

Japan
Nobelpharma

Completed

A Phase II/III Study of Sargramostim

COVID-19

Japan
Osaka University
Hospital Rebagliati

Completed

Assessment of Lung Recruitablity of Acute Respiratory Distress Syndrome With SARS-CoV-2 Pneumonia by Electrical Impedance Tomography

Critical Illness | ARDS

Japan
AstraZeneca

Recruiting

Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)

SARS-CoV-2 Infection

Japan
Kowa Company, Ltd.

Completed

A Phase III Confirmatory Study of K-237

Covid19

Japan, Thailand
National Center for Global Health and Medicine,...

Active, not recruiting

Risk Stratification of COVID-19 Using Urine Biomarkers

Covid19 | Urine | Acute Respiratory Failure With Hypoxia | Biomarker

United States, Brazil, Denmark, Japan, Philippines

3

Subscribe